The report said the FDA’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
read blog articles
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the FDA and Biogen
Leave a Reply
- Trending
- Comments
- Latest
